CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that President and Chief Executive Officer Chuck Wilson will present at the 28th Annual Piper Jaffray Healthcare Conference on November 30, 2016 at 11:30 am ET. The conference is being held at the Lotte New York Palace in New York.
About Unum Therapeutics
Unum Therapeutics uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, which is designed to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in which proprietary, tumor-targeting antibodies are armed to improve their therapeutic potential. The Company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com/.